{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29", "query": { "intervention": "Placebo (treatment C)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 988, "total_pages": 99, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T17:07:16.167Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00813293", "title": "Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "radiofrequency ablation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2009-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2023-06-13", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00813293" }, { "nct_id": "NCT07167693", "title": "Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetes (DM)", "Diabetic Ketoacidosis", "Ketosis Prone Diabetes", "Hyperglycaemia (Diabetic)" ], "interventions": [ { "name": "Arginine hydrochloride", "type": "DRUG" }, { "name": "Sodium Chloride 0.9%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David K Carroll", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-12-19", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07167693" }, { "nct_id": "NCT07619131", "title": "A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Laroprovstat", "type": "DRUG" }, { "name": "Rosuvastatin 1", "type": "DRUG" }, { "name": "Rosuvastatin 2", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Placebo to match rosuvastatin", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 2", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat/Rosuvastatin 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 600, "start_date": "2026-08-12", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 77, "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619131" }, { "nct_id": "NCT03169231", "title": "Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Aging Frailty" ], "interventions": [ { "name": "Longeveron Mesenchymal Stem Cells (LMSCs)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Longeveron Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "70 Years to 85 Years" }, "enrollment_count": 150, "start_date": "2017-07-06", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 7, "location_summary": "Aventura, Florida • Coral Gables, Florida • Fort Myers, Florida + 3 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03169231" }, { "nct_id": "NCT03203330", "title": "A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Degenerative Osteoarthritis" ], "interventions": [ { "name": "TG-C", "type": "BIOLOGICAL" }, { "name": "Placebo Control", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kolon TissueGene, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 535, "start_date": "2018-10-30", "completion_date": "2026-08-18", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03203330" }, { "nct_id": "NCT04885530", "title": "ACTIV-6: COVID-19 Study of Repurposed Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Ivermectin", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Fluticasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Susanna Naggie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 10956, "start_date": "2021-06-08", "completion_date": "2024-04-29", "has_results": true, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 110, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04885530" }, { "nct_id": "NCT05063201", "title": "Cariprazine for Comorbid Cocaine and Opioid Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid-use Disorder", "Cocaine Use Disorder" ], "interventions": [ { "name": "Cariprazine 1.5 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyle Kampman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 26, "start_date": "2022-08-05", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05063201" }, { "nct_id": "NCT05139602", "title": "A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Lutikizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2021-12-28", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05139602" }, { "nct_id": "NCT00645918", "title": "GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Arteriosclerosis", "Acute Coronary Syndrome" ], "interventions": [ { "name": "clopidogrel", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accumetrics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2800, "start_date": "2008-06", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2011-06-16", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00645918" }, { "nct_id": "NCT03310411", "title": "A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Lasmiditan", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" }, { "name": "Placebo for Lasmiditan", "type": "DRUG" }, { "name": "Placebo for Sumatriptan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2017-10-17", "completion_date": "2017-12-23", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-09-30T17:07:16.167Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310411" } ] }